Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access
This new report offers recommendations to ensure access to long-acting technologies throughout the research and development process.
An Activist’s Guide to Shorter Treatment for Drug-Sensitive Tuberculosis
After a decades-long wait, shorter treatment for drug-sensitive tuberculosis (TB) for adults and children is finally possible. Two landmark clinical trials (S31/A5349 and SHINE) have demonstrated that adults, adolescents, and some children can be cured of TB in as little as four months.
Statement from TAG’s TB Project on Today’s WHO Global TB Report
Today's Global TB Report from WHO confirms our worst expectations for how COVID-19 has set back the global TB response. The pandemic has reversed an entire generation of progress. The first year-on-year increase in TB deaths since 2005 is devastating.
The TB Research Engine That Could: Sustaining the Success of TBTC Research in Turbulent Times
This publication explores the critical role the Tuberculosis Trials Consortium holds in increasing the store of knowledge about TB cures and other tools, demonstrates the implications that a lack of funding will have across the TB pipeline, and offers recommendations to ensure the gains made in TB research are not lost.
Landmark TB Trials Results Published in New England Journal of Medicine
Today the New England Journal of Medicine published results of a landmark phase III clinical trial that found a 4-month regimen containing rifapentine and moxifloxacin performed as well as the six-month standard regimen in curing drug-susceptible pulmonary TB.
Community Movements Across Africa, Asia and South America Celebrate Roll-Out of Short-Course, Patient-Friendly TB Preventive Therapy
Advocates and affected communities working towards the global scale-up of short-course TB preventive therapy (TPT) hail the recent announcement of the launch of decently priced, patient-friendly fixed-dose combinations (FDC) of 3HP in five high burden HIV and TB countries.
Open Letter: Urgent Action Necessary to Improve Equitable Access to GeneXpert TB Diagnostics and Achieve 1/4/6×24
A coalition of civil society activists, including TAG, public health leaders, and researchers sent this letter with information about the 1/4/6x24 Campaign...
Finally—A New Four-Month Treatment for Drug-Susceptible TB!
Treatment Action Group (TAG) and the Community Research Advisors Group (CRAG) welcome the news of a safe and effective regimen for shortening tuberculosis (TB) treatment to just four months.
Por fin un nuevo tratamiento de cuatro meses para la tuberculosis sensible a fármacos
El Grupo de Acción para el Tratamiento (TAG, por sus siglas en inglés) y el Grupo de Asesores Comunitarios de Investigación (CRAG, por sus siglas en inglés) se congratulan ante la noticia de un régimen seguro y eficaz capaz de acortar el tratamiento de la tuberculosis (TB) a sólo cuatro meses.
Advancing Access through Market Interventions: Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down
This policy brief examines lessons learned from the Xpert MTB/RIF TB test buy-down and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.